Literature DB >> 9091804

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases.

P J Barnes1, M Karin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9091804     DOI： 10.1056/NEJM199704103361506

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  1069 in total

Review 1.  Series introduction: the transcription factor NF-kappaB and human disease.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

Review 2.  Bridging the gap: composition, regulation, and physiological function of the IkappaB kinase complex.

Authors:  E Zandi; M Karin
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

3.  A role for NF-kappaB-dependent gene transactivation in sunburn.

Authors:  K Abeyama; W Eng; J V Jester; A A Vink; D Edelbaum; C J Cockerell; P R Bergstresser; A Takashima
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

Review 4.  Molecular mechanisms of glucocorticoid action: what is important?

Authors:  R Newton
Journal:  Thorax       Date:  2000-07       Impact factor: 9.139

5.  SCF(beta)(-TrCP) ubiquitin ligase-mediated processing of NF-kappaB p105 requires phosphorylation of its C-terminus by IkappaB kinase.

Authors:  A Orian; H Gonen; B Bercovich; I Fajerman; E Eytan; A Israël; F Mercurio; K Iwai; A L Schwartz; A Ciechanover
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

6.  Sequences between the enhancer and promoter in the long terminal repeat affect murine leukemia virus pathogenicity and replication in the thymus.

Authors:  F K Yoshimura; T Wang; M Cankovic
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

7.  Calpain inhibitor I reduces the development of acute and chronic inflammation.

Authors:  S Cuzzocrea; M C McDonald; E Mazzon; D Siriwardena; I Serraino; L Dugo; D Britti; G Mazzullo; A P Caputi; C Thiemermann
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

Review 8.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

9.  Prevention of fat-induced insulin resistance by salicylate.

Authors:  J K Kim; Y J Kim; J J Fillmore; Y Chen; I Moore; J Lee; M Yuan; Z W Li; M Karin; P Perret; S E Shoelson; G I Shulman
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

Review 10.  Peroxisome proliferator activated receptor gamma: a potential therapeutic target in the management of ischaemic heart disease.

Authors:  J S Sidhu; J C Kaski
Journal:  Heart       Date:  2001-09       Impact factor: 5.994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.